ClinicalTrials.gg
Not yet recruitingNCT07857096RISEUpdated Oct 5, 2026

Rehabilitation Through Individualized Support and Exercise

An interventional study of Tailored physiotherapy program for early mobilization after oral cancer surgery in Oral Cancer and Head and Neck Cancer, sponsored by Universitaire Ziekenhuizen KU Leuven. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Oral cancer, the most prevalent form of head and neck malignancy, represents a major global health burden, with over 370,000 new cases annually according to the World Health Organization. Surgical resection with free flap reconstruction remains the gold standard for curative treatment, yet it often entails significant functional and physical impairment. The surgical procedure often involves tumor resection and reconstruction. Postoperative complications such as dysphagia, reduced masticatory function, and prolonged immobility frequently contribute to fatigue, loss of muscle mass, and delayed recovery, ultimately impacting quality of life and overall prognosis.

Loss of skeletal muscle mass, commonly observed in this patient population, is strongly associated with impaired physical performance, reduced treatment tolerance, and increased postoperative morbidity. Recent evidence underscores that early mobilization and structured physiotherapeutic interventions can mitigate these effects, enhance functional recovery, and reduce length of hospital stay across various surgical populations. In head and neck cancer specifically, early mobilization has been associated with shorter hospitalization and fewer complications, yet practical, standardized physiotherapy protocols remain scarce and poorly defined.

Despite inclusion of early mobilization principles in Enhanced Recovery After Surgery (ERAS) pathways, current head and neck cancer guidelines lack specific recommendations regarding the timing, intensity, and content of postoperative physical activity. Furthermore, evidence on patient compliance and feasibility of such interventions during the acute hospitalization phase is limited.

02

Conditions studied

  • Oral Cancer
  • Head and Neck Cancer

Keywords

  • Mouth Neoplasms
  • early mobilization
  • Physiotherapy
  • perioperative rehabilitation
03

In context

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

This study's planned enrollment of 39 is below the median of 60 across 313 interventional studies indexed under Mouth Neoplasms.

Browse Mouth Neoplasms studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed oral cancer.
  • Planned free fibula or DCIA flap reconstruction.
  • Ability to provide written .
  • Sufficient comprehension of Dutch to complete questionnaires.

Exclusion criteria

Exclusion criteria:

  • Severe psychiatric or neurocognitive impairment (e.g., dementia, Korsakoff syndrome, schizophrenia).
  • Hemodynamic instability or to mobilization.
  • Pre-existing neuromuscular disorders severely limiting mobility.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Experimental

    Patients get a tailored physiotherapy program for early mobilization after oral cancer surgery

    Other: Tailored physiotherapy program for early mobilization after oral cancer surgery

Interventions

  • OtherTailored physiotherapy program for early mobilization after oral cancer surgery

    Participants allocated to the intervention group will receive a structured, multicomponent exercise programme during the perioperative period in addition to usual care. The programme includes individually tailored aerobic, resistance, flexibility and functional exercises, supervised by trained healthcare professionals and progressively adapted according to the participant's clinical condition and recovery.

06

What researchers measure

Primary outcomes

  1. Achievement of the highest exercise progression level

    The percentage of participants who achieve the highest exercise progression level of the postoperative physiotherapy programme before hospital discharge will be reported. The highest progression level is defined as Level 4. The percentage will be calculated as the number of participants achieving this level divided by the total number of participants included in the primary feasibility analysis (n=35), multiplied by 100.

    Time frame: From the first postoperative physiotherapy session until hospital discharge, anticipated from day 1 to 10 after surgery.

  2. Patient-reported acceptability of the intervention

    Patient-reported acceptability of the physiotherapy programme will be assessed using the Acceptability of Intervention Measure (AIM). The AIM consists of four items, each rated from 1 (completely disagree) to 5 (completely agree). The participant-level score will be calculated as the mean of the four item scores, ranging from 1 to 5. Higher scores indicate greater perceived acceptability.

    Time frame: At hospital discharge, anticipated 10 days after surgery.

  3. Patient-reported appropriateness of the intervention

    Patient-reported appropriateness of the physiotherapy programme will be assessed using the Intervention Appropriateness Measure (IAM). The IAM consists of four items, each rated from 1 (completely disagree) to 5 (completely agree). The participant-level score will be calculated as the mean of the four item scores, ranging from 1 to 5. Higher scores indicate greater perceived appropriateness.

    Time frame: At hospital discharge, anticipated 10 days after surgery.

  4. Patient-reported feasibility of the intervention

    Patient-reported feasibility of the physiotherapy programme will be assessed using the Feasibility of Intervention Measure (FIM). The FIM consists of four items, each rated from 1 (completely disagree) to 5 (completely agree). The participant-level score will be calculated as the mean of the four item scores, ranging from 1 to 5. Higher scores indicate greater perceived feasibility.

    Time frame: At hospital discharge, anticipated 10 days after surgery.

  5. Adherence to prescribed physiotherapy sessions

    Adherence will be assessed as the percentage of prescribed postoperative physiotherapy sessions completed by each participant. This percentage will be calculated as the number of completed sessions divided by the number of prescribed and clinically eligible sessions during the postoperative hospital stay, multiplied by 100. A completed session is defined as a supervised physiotherapy session that is initiated and delivered as planned or with clinically indicated adaptations. Sessions that are initiated but terminated before completion will be classified as incomplete, with the reason for termination recorded. Sessions withheld or terminated because the participant is clinically ineligible for physiotherapy or because of safety concerns will be reported separately and excluded from the denominator. Scores range from 0% to 100%, with higher percentages indicating greater adherence.

    Time frame: From the first prescribed postoperative physiotherapy session until hospital discharge, anticipated from day 1 to 10 after surgery.

  6. Therapist-rated adherence to physiotherapy

    Therapist-rated in-session engagement will be assessed immediately after each postoperative physiotherapy session using the Sport Injury Rehabilitation Adherence Scale (SIRAS). The SIRAS consists of three items, each scored from 1 to 5. Item scores are summed to obtain a session-level total score ranging from 3 to 15, with higher scores indicating greater in-session engagement. The reported participant-level outcome will be the mean of the session-level total scores across all assessed sessions.

    Time frame: Immediately after each postoperative physiotherapy session, from the first session until hospital discharge, anticipated from day 1 to 10 after surgery.

Secondary outcomes

  1. Objectively measured physical activity

    Physical activity will be continuously assessed using the Activ8 Physical Activity Monitor G2. Activity data will be collected throughout the perioperative period to quantify daily physical activity and sedentary behaviour. Participant diaries will be used to support interpretation of activity monitor data during the preoperative and post-discharge periods.

    Time frame: From baseline (8 days before surgery) until the end of follow-up (10 days after discharge).

  2. Anxiety symptoms

    Anxiety symptoms will be assessed preoperatively using the Generalized Anxiety Disorder 2-item scale (GAD-2), with a total score ranging from 0 to 6. Higher scores indicate greater anxiety symptom severity and therefore a worse outcome. Participants scoring ≥3 will additionally complete the Generalized Anxiety Disorder 7-item scale (GAD-7), with a total score ranging from 0 to 21. Higher GAD-7 scores indicate greater anxiety symptom severity and therefore a worse outcome.

    Time frame: At baseline, 8 days before surgery

  3. Baseline physical activity

    Baseline physical activity and sedentary behaviour will be assessed using the Simple Physical Activity Questionnaire (SIMPAQ). The SIMPAQ assesses time spent across five activity domains: time in bed, sedentary time, walking, structured exercise, and incidental physical activity. Outcomes are reported as time spent in each activity domain rather than as a total score; therefore, no overall minimum or maximum score or direction of better outcome applies.

    Time frame: At baseline, 8 days before surgery

  4. Motivation for physical activity

    Motivation for physical activity will be assessed using the Behavioral Regulation in Exercise Questionnaire-3 (BREQ-3). The questionnaire assesses six forms of motivation: amotivation, external regulation, introjected regulation, identified regulation, integrated regulation, and intrinsic regulation. Each subscale is scored from 0 to 4. Higher scores indicate a greater presence of the respective type of motivation. Higher identified, integrated, and intrinsic regulation scores reflect greater autonomous motivation (better outcomes), whereas higher amotivation reflects lower motivation (worse outcome). External and introjected regulation represent more controlled forms of motivation and cannot be uniformly interpreted as better or worse outcomes. No overall BREQ-3 total score is calculated.

    Time frame: At baseline, 8 days before surgery, and at the start of the intervention, anticipated 1 day after surgery.

  5. Functional lower limb performance measured by the Five Times Sit-to-Stand Test

    Functional lower limb performance will be assessed using the Five Times Sit-to-Stand Test (5xSTS). The time required to complete five consecutive sit-to-stand repetitions will be recorded in seconds. Shorter completion times indicate better functional lower limb performance. Completion times will be reported at each assessment time point.

    Time frame: At baseline, 8 days before surgery, and at hospital discharge, anticipated 10 days after surgery.

  6. Functional exercise capacity measured by the Six-Minute Walk Test

    Functional exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). The total distance walked during six minutes will be recorded in metres. Greater walking distances indicate better functional exercise capacity. Walking distances will be reported at each assessment time point.

    Time frame: At baseline, 8 days before surgery, and at hospital discharge, anticipated 10 days after surgery.

  7. Handgrip strength

    Handgrip strength will be assessed using a Jamar Hydraulic Hand Dynamometer and recorded in kilograms. Three attempts will be performed for each hand at each assessment time point. The mean of the three attempts will be calculated separately for the right and left hand, and results will be reported separately by hand. Higher values indicate greater handgrip strength.

    Time frame: At baseline, 8 days before surgery, and at hospital discharge, anticipated 10 days after surgery.

  8. Pain intensity

    Pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain. Higher scores indicate greater pain intensity and therefore a worse outcome. Pain scores will be recorded three times daily from the preoperative baseline assessment until 10 days after hospital discharge.

    Time frame: From baseline (8 days before surgery) until the end of follow-up (10 days after discharge).

  9. Perceived exertion during physiotherapy

    Perceived exertion will be assessed using the Borg Rating of Perceived Exertion (RPE) scale at the end of each supervised postoperative physiotherapy session. The scale ranges from 6 (no exertion) to 20 (maximal exertion), with higher scores indicating greater perceived exertion. The reported participant-level outcome will be the mean of the session-level ratings across all assessed postoperative physiotherapy sessions.

    Time frame: At the end of each supervised postoperative physiotherapy session, from the first session until hospital discharge, anticipated from day 1 to 10 after surgery.

  10. Length of hospital stay

    Length of hospital stay will be recorded as the number of days from surgery until hospital discharge.

    Time frame: From the day of surgery until hospital discharge, anticipated 10 days after surgery.

  11. Postoperative complications

    Postoperative complications will be recorded and classified according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events are graded from 1 to 5, with higher grades indicating greater severity: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event). Higher grades therefore indicate a worse outcome. No overall score is calculated.

    Time frame: From surgery until the end of follow-up (12 weeks after surgery)

07

Study locations

1 site
  • UZ Leuven
    Leuven, 3000, Belgium
    • Lina Van Lint · Contactlina.vanlint@kuleuven.be · 0475349544
    • Jeroen Van Dessel, Dr. · Sub investigator
    • Robin Willaert, Prof. Dr. · Principal investigator
    • Lina Van Lint, MSc · Sub investigator
    • Lynn Christiaens, MSc · Sub investigator
    • Auke Van Mierlo, Dr. · Sub investigator
    • Karla Van de Velde, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to participant confidentiality, ethical considerations, and institutional data protection policies.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2029, 27 months later.

Of 98 non-industry interventional studies with no phase under Mouth Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 97. This study's planned 27 months is close to that.

Counting every sponsor, half of 99 studies reached it within 30 months; a quarter within 17 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Oct 5, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857096
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Lina Van Lint, MSc
Contact
lina.vanlint@kuleuven.be
003216342475

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion